Spine Devices Market: Stryker’s Strategic Exit and Industry Trends

The spine devices market is undergoing significant changes, with key players adapting their strategies in response to shifting industry dynamics. One such notable development comes from Stryker, which recently made a strategic exit by selling its U.S. spinal implants business to Viscogliosi Bros., LLC, a family investment firm focused on neuro-musculoskeletal technology. This deal also includes a bid to acquire Stryker’s spinal products in France and the formation of VB Spine, LLC, which will have exclusive access to Stryker’s robotic Mako Spine and Copilot portfolio for use with its implants.

This move reflects a shift in Stryker’s strategy within the competitive market. With increased competition and slow market growth, Stryker has decided to reassess its position in the spine segment and refocus its resources on other areas with higher growth potential. This article will delve into the strategic reasoning behind this deal and its implications for the spine devices market.

The Spine Devices Market Landscape

The spine devices market is currently dominated by a few major players, with Medtronic, Globus Medical, and DePuy Synthes controlling over half of the market share. However, the remaining portion is fragmented among a wide range of competitors, including Stryker’s former spine business. Despite the large share controlled by these major players, the market’s growth is modest. According to LSI’s Global Market Analysis and Projections, the global spine devices market is expected to grow at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2029. This is slower than the overall medtech market, which is expected to grow at a CAGR of 6.6% during the same period.

Stryker’s decision to sell its U.S. spine business is part of a broader strategy centered on Stryker’s M&A activities, aligning with the company’s ongoing focus on expanding its presence in faster-growing markets.

In the United States, while spine surgical procedure volumes continue to grow, they are increasing at a slower pace. According to LSI’s Global Surgical Procedure Volumes Database, approximately 1.7 million spine procedures — including fusions, discectomies, decompressions, and fracture repairs — were performed in 2024. However, these volumes are only expected to grow at a modest 2.0% CAGR through 2029, which is slower than the growth of the U.S. 65+ population.

In contrast, global spine procedures are expected to see more substantial growth, with projections showing an 8.3% CAGR during the same period. This suggests that there are opportunities for expansion in regions outside the United States, where spine surgery is increasing more rapidly due to improving healthcare access and aging populations.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/spine-devices-market-strykers-strategic-exit-and-industry-trends 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more